I wanted to share with you another novel clinical trial using a compound targeting two receptors on tumor cells. Both receptors we know very well: one is HER2, the target for Herceptin, and the other one is EGFR, the target for Erbitux.
One compound targeting both receptors is on the market known as Tykerb® (lapatinib) which is approved for breast cancer patients in combination with Xeloda® (capecitabine). Read the rest of this entry »

